Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open …
Background Dysregulated inflammation is associated with poor outcomes in COVID-19. We
aimed to assess the efficacy of namilumab (a granulocyte-macrophage colony stimulating …
aimed to assess the efficacy of namilumab (a granulocyte-macrophage colony stimulating …
Early use of sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial
N Merchante, S Cárcel, JC Garrido-Gracia… - Antimicrobial Agents …, 2022 - Am Soc Microbiol
The objective of this study was to investigate the efficacy and safety of early treatment with
sarilumab, added to standard of care (SOC), in hospitalized adults with COVID-19. Methods …
sarilumab, added to standard of care (SOC), in hospitalized adults with COVID-19. Methods …
Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial
Background Patients with COVID-19 pneumonia can have increased inflammation and
elevated cytokines, including interleukin (IL)-6, which might be deleterious. Thus, sarilumab …
elevated cytokines, including interleukin (IL)-6, which might be deleterious. Thus, sarilumab …
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group, PW Horby… - Medrxiv, 2021 - medrxiv.org
Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …
Efficacy and safety of sarilumab in patients with COVID19 pneumonia: a randomized, phase III clinical trial (SARTRE study)
A Sancho-López, AF Caballero-Bermejo… - Infectious diseases and …, 2021 - Springer
Introduction SARS-CoV-2 pneumonia is often associated with hyper-inflammation. The
cytokine-storm-like is one of the targets of current therapies for coronavirus disease 2019 …
cytokine-storm-like is one of the targets of current therapies for coronavirus disease 2019 …
Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients-mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19–Repurposed Drugs …
S Kulkarni, M Fisk, M Kostapanos, E Banham-Hall… - Trials, 2020 - Springer
Objectives To determine if a specific immunomodulatory intervention reduces progression of
COVID-19-related disease to organ failure or death, compared to standard of care (SoC) …
COVID-19-related disease to organ failure or death, compared to standard of care (SoC) …
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
FX Lescure, H Honda, RA Fowler, JS Lazar… - The Lancet …, 2021 - thelancet.com
Background Elevated proinflammatory cytokines are associated with greater COVID-19
severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor …
severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor …
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
O Abani, A Abbas, F Abbas, M Abbas, S Abbasi… - The Lancet, 2022 - thelancet.com
Background Casirivimab and imdevimab are non-competing monoclonal antibodies that
bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike …
bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike …
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
Objectives To assess the safety and efficacy of interleukin (IL)− 6 blockade with sarilumab in
patients with severe COVID-19 pneumonia and systemic hyperinflammation. Methods We …
patients with severe COVID-19 pneumonia and systemic hyperinflammation. Methods We …
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
Z Temesgen, CD Burger, J Baker, C Polk… - The Lancet …, 2022 - thelancet.com
Background The pathophysiology of COVID-19 includes immune-mediated
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte …
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte …